Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMP9 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intratumoral, Ophthalmic, Topical
01
Overview
MMP9 siRNA refers to small interfering RNA molecules designed to specifically target and silence the expression of matrix metalloproteinase-9 (MMP-9). MMP-9 is a zinc-dependent endopeptidase involved in the degradation of extracellular matrix components, and its overexpression is associated with pathological processes such as chronic non-healing wounds (e.g., diabetic foot ulcers), tissue scarring, and cancer metastasis. By utilizing RNA interference (RNAi), MMP9 siRNA mediates the sequence-specific degradation of MMP9 mRNA, thereby reducing MMP-9 protein levels and enzymatic activity. This therapeutic approach is being investigated in preclinical research for various indications, including diabetic wound healing, corneal and hypertrophic skin scarring, and oncology.
- Other names
- MMP-9 siRNAMMP9 siRNAMMP 9 siRNAmatrix metalloproteinase-9 siRNAsiRNA targeting MMP-9siRNA targeting MMP9
02
Targets
MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on MMP9 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMP9 siRNA.